证券研究报告 | 公司动态点评 2025 年 08 月 27 日 | 买入（维持评级） | | | --- | --- | | 股票信息 | | | 行业 | 农林牧渔 | | 2025 年 8 月 26 日 收 盘 价 | 11.31 | | （元） | | | 总市值（百万元） | 9,105.26 | | 流通市值（百万元） | 7,124.89 | | 总股本（百万股） | 805.06 | | 流通股本（百万股） | 629.96 | | 近 3 月 日均 成交 额（ 百万 | 101.98 | | 元） | | 股价走势 -12% -5% 2% 9% 15% 22% 29% 36% 2024-08 2024-12 2025-04 2025-08 华统股份 沪深300 华统股份（002840.SZ） 养殖业务实现盈利，降本增效持续兑现 | 财务指标 | 2023A | 2024A | 2025E | 2026E | 2027E | | --- | --- | --- | --- | --- | --- | | 营业收入（百万元） | 8,578 | 9,092 | 9,943 | 11,490 | ...

Investment Rating - The report maintains a "Buy" rating for the company, indicating an expected stock price increase of over 15% relative to the industry index in the next six months [5][17]. Core Insights - The company is experiencing a significant increase in demand from North American customers, particularly in its medical device segment, which is expected to drive revenue growth [3][9]. - The core product, Fibroscan, is anticipated to see continued growth as the MASH new drug accelerates its global promotion, leading to a breakthrough in other regions [9]. - The company is projected to achieve revenues of 1.727 billion, 2.457 billion, and 3.629 billion yuan from 2025 to 2027, with corresponding net profits of 188 million, 290 million, and 462 million yuan, reflecting year-on-year growth rates of 65.8%, 54.4%, and 59.4% respectively [9]. Financial Performance Summary - For 2023, the company expects revenue of 1.154 billion yuan, with a year-on-year growth rate of 14.4%. By 2027, revenue is projected to reach 3.629 billion yuan, with a growth rate of 47.7% [1]. - The net profit attributable to the parent company is forecasted to grow from 102 million yuan in 2023 to 462 million yuan in 2027, with a significant increase in the growth rate from 3.8% in 2023 to 59.4% in 2027 [1]. - The company's return on equity (ROE) is expected to improve from 9.6% in 2023 to 21.1% in 2027, indicating enhanced profitability [1]. Business Segment Performance - The medical device segment reported a revenue of 482 million yuan in the first half of 2025, marking a year-on-year increase of 13.8%. This growth is attributed to increased sales and management investments, as well as the approval of the MASH new drug [3]. - The pharmaceutical and medical services segment achieved a revenue of 231 million yuan in the first half of 2025, with a growth rate of approximately 5.62%. The e-commerce channel for proprietary drugs saw a remarkable increase of 59.23% [4].

Investment Rating - The report maintains a "Buy" rating for the company, expecting a stock price increase of over 15% relative to the industry index in the next six months [5][19]. Core Viewpoints - The company's revenue and profit have shown significant year-on-year growth in the first half of 2025, driven primarily by the continued expansion of long-chain dicarboxylic acid products [2][11]. - The company is focusing on technological innovation and has made substantial progress in various R&D projects, which are expected to support future business expansion [4][8]. - The company is actively collaborating with partners to promote the application of bio-based polyamide and its composite materials, enhancing its market position [8][11]. Financial Performance Summary - For the first half of 2025, the company reported a revenue of 1.671 billion, a year-on-year increase of 15.68%, and a net profit attributable to shareholders of 309 million, up 24.74% year-on-year [1][2]. - The gross profit margin for the first half of 2025 was 33.85%, an increase of 2.63 percentage points compared to the same period in 2024 [2]. - The company’s operating cash flow decreased by 22.08% year-on-year, while the cash and cash equivalents balance increased by 87.48% year-on-year to 8.684 billion [3]. R&D and Innovation Summary - The company invested 123 million in R&D in the first half of 2025, representing 7.37% of its revenue, with significant advancements in green dicarboxylic acid and bio-based polyamide projects [4][8]. - The company has established partnerships to develop bio-based composite materials for various applications, including energy storage and automotive components [8][9]. Future Growth Prospects - The company is expected to achieve revenues of 3.537 billion, 4.704 billion, and 5.704 billion for the years 2025, 2026, and 2027, respectively, with corresponding net profits of 677 million, 817 million, and 1.012 billion [1][11]. - The ongoing construction of the Shanxi Synthetic Biology Industrial Park, with a total planned investment of 80 billion, is anticipated to enhance the company's production capacity and market leadership [9].

证券研究报告| 公司动态点评 2025 年 08 月 27 日 圣泉集团（605589.SH） 1H25 公司业绩实现较高增速，合成树脂和先进电子材料板块表现 优异 | 财务指标 | 2023A | 2024A | 2025E | 2026E | 2027E | | --- | --- | --- | --- | --- | --- | | 营业收入（百万元） | 9,120 | 10,020 | 11,575 | 14,371 | 16,270 | | 增长率 yoy（%） | -5.0 | 9.9 | 15.5 | 24.2 | 13.2 | | 归母净利润（百万元） | 789 | 868 | 1,286 | 1,425 | 1,672 | | 增长率 yoy（%） | 12.2 | 9.9 | 48.1 | 10.8 | 17.4 | | ROE（%） | 8.4 | 8.4 | 11.5 | 11.5 | 12.2 | | EPS 最新摊薄（元） | 0.93 | 1.03 | 1.52 | 1.68 | 1.98 | | P/E（倍） | 34.4 | 31.3 | 21.1 | 19.1 | 1 ...

Investment Rating - The report maintains an "Accumulate" rating for the company [5] Core Views - The company has achieved high profitability from overseas energy storage orders, and despite disruptions, it maintains its annual targets [1] - The inverter market is recovering, with strong demand in traditional markets and contributions from new segments [2] - The energy storage segment has seen significant revenue growth, supported by high-margin orders and a strong brand effect [3] - The company is actively adapting to policy changes affecting its power station development business and is exploring new opportunities in AIDC [4] Financial Summary - Revenue is projected to grow from 72,251 million yuan in 2023 to 110,546 million yuan in 2027, with a CAGR of approximately 8.5% [1] - Net profit is expected to increase from 9,440 million yuan in 2023 to 14,035 million yuan in 2027, reflecting a growth rate of 1.3% in the final year [1] - The company’s return on equity (ROE) is forecasted to decline from 32.6% in 2023 to 18.7% in 2027 [1] - The earnings per share (EPS) is anticipated to rise from 4.55 yuan in 2023 to 6.77 yuan in 2027 [1] Segment Performance - The inverter segment generated revenue of 153.27 billion yuan in the first half of 2025, with a year-on-year growth of 17.06% and a gross margin of 35.74% [2] - The energy storage systems segment achieved revenue of 178.03 billion yuan in the first half of 2025, marking a year-on-year increase of 127.78% [3] - The company’s new energy investment and development business reported a revenue of 83.98 billion yuan in the first half of 2025, a decrease of 6.22% year-on-year [4]

证券研究报告 | 公司动态点评 2025 年 08 月 27 日 泰胜风能（300129.SZ） 产能建设推进顺利订单充裕，海外海上出货放量可期 | 财务指标 | 2023A | 2024A | 2025E | 2026E | 2027E | | --- | --- | --- | --- | --- | --- | | 营业收入（百万元） | 4,813 | 4,838 | 6,061 | 6,937 | 8,030 | | 增长率 yoy（%） | 53.9 | 0.5 | 25.3 | 14.4 | 15.8 | | 归母净利润（百万元） | 292 | 182 | 308 | 446 | 550 | | 增长率 yoy（%） | 6.4 | -37.8 | 69.4 | 44.7 | 23.4 | | ROE（%） | 6.8 | 4.2 | 6.5 | 8.8 | 9.9 | | EPS 最新摊薄（元） | 0.31 | 0.19 | 0.33 | 0.48 | 0.59 | | P/E（倍） | 24.9 | 40.1 | 23.7 | 16.4 | 13.2 | | P/B（倍） | 1.7 | ...

证券研究报告 | 公司动态点评 2025 年 08 月 26 日 龙蟠科技（603906.SH） 铁锂出海迎收获，碳酸锂步入正轨 | 财务指标 | 2023A | 2024A | 2025E | 2026E | 2027E | | --- | --- | --- | --- | --- | --- | | 营业收入（百万元） | 8,729 | 7,673 | 8,686 | 10,447 | 12,386 | | 增长率 yoy（%） | -38.0 | -12.1 | 13.2 | 20.3 | 18.6 | | 归母净利润（百万元） | -1,233 | -636 | 88 | 284 | 640 | | 增长率 yoy（%） | -263.8 | 48.5 | 113.8 | 224.4 | 125.2 | | ROE（%） | -36.2 | -19.9 | 2.6 | 7.9 | 15.1 | | EPS 最新摊薄（元） | -1.80 | -0.93 | 0.13 | 0.42 | 0.93 | | P/E（倍） | -8.2 | -15.8 | 114.8 | 35.4 | 15.7 | | ...

扣非盈利同比提升，新能源量增对冲价减 | 财务指标 | 2023A | 2024A | 2025E | 2026E | 2027E | | --- | --- | --- | --- | --- | --- | | 营业收入（百万元） | 180,999 | 179,182 | 176,287 | 182,102 | 187,018 | | 增长率 yoy（%） | -7.0 | -1.0 | -1.6 | 3.3 | 2.7 | | 归母净利润（百万元） | 5,609 | 9,831 | 7,422 | 8,222 | 8,822 | | 增长率 yoy（%） | 98.8 | 75.3 | -24.5 | 10.8 | 7.3 | | ROE（%） | 10.0 | 12.7 | 9.4 | 9.4 | 9.3 | | EPS 最新摊薄（元） | 0.31 | 0.55 | 0.42 | 0.46 | 0.49 | | P/E（倍） | 15.3 | 8.7 | 11.6 | 10.5 | 9.7 | | P/B（倍） | 1.8 | 1.5 | 1.4 | 1.3 | 1.1 | 资料来源：公司财报， ...

Investment Rating - The report maintains a rating of "Accumulate" for the company [5] Core Views - The company has demonstrated significant profit growth in Q2 2025, with a revenue of 2.223 billion yuan (up 2.55% year-on-year) and a net profit attributable to shareholders of 169 million yuan (up 0.96% year-on-year) [1] - The core business of the company, which is the sale of malt products, achieved a revenue of 2.135 billion yuan in H1 2025 (up 1.27% year-on-year), accounting for 96.03% of total revenue [2] - The company is positioned as the largest malt supplier in Asia, benefiting from scale advantages, strong customer barriers, and a unique cost structure [4] Financial Performance Summary - Revenue is projected to reach 4.426 billion yuan in 2025, with a year-on-year growth of 3.4%, and net profit attributable to shareholders is expected to be 334 million yuan, reflecting an 11.4% increase [4] - The company's gross margin and net profit margin for Q2 2025 were 13.24% and 8.17%, respectively, both showing year-on-year increases [2] - The company has optimized its production capacity to align with the trend of high-end beer consumption, with a total production capacity of 1.08 million tons per year [3] Future Outlook - The company is expected to benefit from cost advantages in the short term and increased demand for high-end beer in the long term [3] - The dividend payout ratio is projected to increase to 50.27% in 2024, indicating a commitment to returning value to shareholders [3] - The company is actively pursuing a strategy to enhance its product structure towards high-end and customized products [3]

大储羽翼丰满，优质订单支撑利润体量。公司储能业务 25 年上半年实现出货 约 3.1GWh，同比增长 19.23%，贡献营收约 44.3 亿元，同比+8.55%，其中 二季度储能交付 2.2GWh，环比增长超 140%，公司储能订单优质，单价高、 盈利好，叠加海外拉货节奏旺盛，测算 Q2 储能板块毛利率仍维持在 30%的 水平区间，对应单位盈利约为 0.3 元/Wh，继续领跑行业。截至报告期末， 阿特斯储能科技（e-STORAGE）已签署合同在手订单金额为 30 亿美元，在 美洲、澳洲、欧洲均有新签大规模项目，但考虑到主力市场当地补贴政策、 贸易变化的影响，保守调整全年出货预期至 7-9GWh，预计 25Q3 储能出货 2.1-2.3GWh。 坚持利润优先原则，组件业务限产保价。利润优先是公司在光伏领域的首要 经营原则，报告期内，公司出货组件 14.8GW，同比基本持平，贡献营业收 入约 143.62 亿元，同比-7.34%，对应 Q2 组件出货约 7.9GW，环比增长约 15%，得益于公司组件在北美市场出货量、市占率的增长韧性，测算 Q2 公 司组件毛利率明显改善，综合单瓦利润约为 0.02 元。展望后续， ...